Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 1, 2011, Pages 123-127

  Luisetti, Maurizio ^a   Kroneberg, Philipp ^b   Suzuki, Takuji ^c   Kadija, Zamir ^a   Muellinger, Bernhard ^b   Campo, Ilaria ^a   Gleske, Juliane ^b   Rodi, Giuseppe ^a   Zimlich, William C ^b   Mariani, Francesca ^a   Ferrari, Fabio ^d   Frey, Manuel ^b   Trapnell, Bruce C ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Activaero GmbH   (Germany)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Aerosol delivery of drugs; Modeling of drug deposition; Pulmonary alveolar proteinosis

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STAT5 PROTEIN;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STRUCTURE; GRAVIMETRY; HUMAN; LASER DIFFRACTION; LUNG ALVEOLUS PROTEINOSIS; LUNG DEPOSIT; MOLECULAR WEIGHT; NEBULIZER; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REPRODUCIBILITY;

AEROSOLS; ANIMALS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LUNG; MICE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PULMONARY ALVEOLAR PROTEINOSIS; RECOMBINANT PROTEINS;

EID: 79251594597     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.08.004     Document Type: Article

References (23)

1. Trapnell B.C., Whittset J.A., Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003, 349:2527-2539.
2. Kitamura T., Tanaka N., Watanabe J., Uchida K., Kanegasaki S., Yamada Y., et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999, 190:875-880.
3. Sakagami T., Uchida K., Suzuki T., Carey B.C., Wood R.E., Wert S.E., et al. Human GM-CSF autoantibodies and pulmonary alveolar proteinosis. N Engl J Med 2009, 361:2679-2681.
4. Seymour J.F., Presneill J.J. Pulmonary alveolar proteinosis. Progress in the first 44 years. Am J Respir Crit Care Med 2002, 166:215-235.
5. Beccaria M., Luisetti M., Rodi G., Corsico A., Zoia M.C., Colato S., et al. Long term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004, 23:526-531.
6. Luisetti M, Trapnell BC. Pulmonary alveolar proteinosis. In: Interstitial lung disease 5th ed. Edited by Schwarz MI, King TE Jr, in press.
7. International Commission on Radiological Protection Human respiratory model for radiological protection. Ann ICRP 1994, 24:1-120.
8. Köbrich R., Rudolf G., Stahlhofen W. A mathematical model of mass deposition in man. Ann Occup Hyg 1994, 38:15-23.
9. Fleming J.S., Epps B.P., Conway J.H., Martonen T.B. Comparison of SPECT aerosol deposition data with a human respiratory tract model. J Aerosol Med 2006, 19:268-278.
10. Shibata Y., Berclaz P.Y., Chroneos Z.C., Yoshida M., Whitsett J.A., Trapnell B.C. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001, 15:557-567.
11. Suzuki T., Sakagami T., Rubin B.K., Nogee L.M., Wood R.E., Zimmerman S.L., et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008, 205:2703-2710.
12. Seymour J.F., Dunn A.R., Vincent J.M., Presneill J.J., Pain M.C. Efficacy of granulocyte-macrophage colony-stimulating-factor in acquired alveolar proteinosis. N Engl J Med 1996, 335:1924-1925.
13. Kavuru M.S., Sullivan E.J., Piccin R., Thomassen R.J., Stoller J.K. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000, 161:1143-1148.
14. Seymour J.F., Presneiil J.J., Schoch O.D., Downie G.H., Moore P.E., Doyle I.R., et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating-factor in patients with idiopathic acquired pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2001, 163:524-531.
15. Ventaketashiah S.B., Yan T.D., Bonfield T.L., Thomassen M.J., Meziane M., Czich C., et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006, 130:227-237.
16. Tazawa R., Hamano E., Arai T., Ohta H., Ishimito O., Uchida K., et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005, 171:1142-1149.
17. Wylam M.E., Ten R., Prakash U.B.S., Nadrous H.F., Clawson M.L., Anderson P.M. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006, 27:585-593.
18. Tazawa R., Trapnell B.C., Inoue Y., Arai T., Takada T., Nasuhara Y., Hizawa N., Kasahara W., Tatsumi K., Hojo M., Ishii H., Yokoba M., Tanaka N., Yamaguchi E., Eda R., Tsuchihashi Y., Morimoto K., Akira M., Terada M., Ohtsuka J., Ebina M., Kaneko C., Nukiwa T., Krischer J.P., Akazawa K., Nakata K. Inhaled granulocyte-macrophage colony-stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010, 181:1345-1354.
19. Scheuch G., Meyer T., Mullinger B. Controlled inhalation improves peripheral deposition. J Aerosol Sci 2001, 14:388.
20. Brand P., Schulte M., Wencker M., Herpich C.H., Klein G., Hanna K., et al. Lung deposition of α1-proteinase inhibitor in cystic fibrosis and α1-antitrypsin deficiency. Eur Respir J 2009, 34:354-360.
21. Griese M., Latzin P., Kappler M., Weckerle K., Hienzlmaier T., Bernhardt T., et al. α1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007, 29:240-250.
22. Frankeberger M., Heimbek I., Moller W., Mamidi S., Kassner G., Pukelshiem K., et al. Inhaled all-trans retinoic acid in an individual with severe emphysema. Eur Respir J 2009, 34:1487-1489.
23. Dopfer R., Brand P., Mullinger B., Hunger T., Haussermann S., Meyer T., et al. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. J Physiol Pharmacol 2007, 58(Suppl. 5):141-154.